A recent study suggests that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional lifestyle regimens.
Findings released in a leading medical journal demonstrates that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Users buying such medications need to be informed of the risk of quick rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to starting weight within about 18 months.
Analyzing Therapies
The analysis, which examined 37 of trials involving thousands of patients, compared the effects of these new drugs with older methods.
Scientists point out that people who shed pounds through diet and exercise generally have a less rapid creep back—approximately 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists propose the way of the drugs accounts for the heightened weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals say that, considering the high risk of relapse, the treatment is often ongoing.
This perspective is reinforced by drug manufacturers, who state that the results "highlight the long-term character of obesity," similar to managing conditions like high blood pressure.
User Experiences
Users who have discontinued the medication report a intense return of cravings.
"It was like a trigger activating and I was suddenly starving," recalled a patient.
This difficulty is worsened if patients have not adopted permanent lifestyle or habit modifications during treatment.
Growing Use
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are potent agents for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle management.
